RT Journal Article
SR Electronic
T1 Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.22.21259318
DO 10.1101/2021.06.22.21259318
A1 Cadegiani, Flávio Adsuara
A1 do Nascimento Fonseca, Daniel
A1 McCoy, John
A1 Zimerman, Ricardo Ariel
A1 Mirza, Fatima Nadeem
A1 do Nascimento Correia, Michael
A1 Barros, Renan Nascimento
A1 Onety, Dirce Costa
A1 Israel, Karla Cristina Petruccelli
A1 de Almeida, Brenda Gomes
A1 Guerreiro, Emilyn Oliveira
A1 Medeiros, José Erique Miranda
A1 Nicolau, Raquel Neves
A1 Nicolau, Luiza Fernanda Mendonça
A1 Cunha, Rafael Xavier
A1 Barroco, Maria Fernanda Rodrigues
A1 da Silva, Patrícia Souza
A1 de Souza Ferreira, Gabriel
A1 da Costa Alcântara, Flavio Renan Paula
A1 Ribeiro, Ângelo Macedo
A1 de Almeida, Felipe Oliveira
A1 de Souza Silva, Adailson Antonio
A1 do Rosario, Suzyane Serfaty
A1 de Souza Paulain, Raysa Wanzeller
A1 Reis, Alessandra
A1 Li, Marissa
A1 Thompson, Claudia Elizabeth
A1 Nau, Gerard J.
A1 Wambier, Carlos Gustavo
A1 Goren, Andy
YR 2021
UL http://medrxiv.org/content/early/2021/06/22/2021.06.22.21259318.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that treatment with proxalutamide, a non-steroidal androgen receptor antagonist, accelerates viral clearance and clinical remission in outpatients with coronavirus disease 2019 (COVID-19) compared to placebo. The effects in hospitalized COVID-19 patients were unknown.Methods Men and women hospitalized but not requiring mechanical ventilation were randomized (1:1 ratio) to receive 300 mg of proxalutamide per day or placebo for 14 days. The study was conducted at eight sites in the state of Amazonas, Brazil. The primary outcome measure was the clinical status (8-point ordinal scale) at 14-days post-randomization. The primary efficacy endpoint was the 14-day recovery ratio (alive hospital discharge [scores 1, 2]).Findings A total of 645 patients were randomized (317 received proxalutamide, 328 placebo) and underwent intention-to-treat analysis. The 14-day median ordinal scale score in the proxalutamide group was 1 (interquartile range [IQR]=1–2) versus 7 (IQR=2–8) for placebo, P<0.001. The 14-day recovery rate was 81.4% for proxalutamide and 35.7% for placebo (recovery ratio, 2.28; 95% CI 1.95–2.66 [P<0.001]). The 28-day all-cause mortality rate was 11.0% for proxalutamide versus 49.4% for placebo (hazard ratio, 0.16; 95% CI 0.11–0.24). The median post-randomization time to recovery was 5 days (IQR=3– 8) for proxalutamide versus 10 days (IQR=6–15) for placebo.Interpretation Hospitalized COVID-19 patients not requiring mechanical ventilation receiving proxalutamide had a 128% higher recovery rate than those treated with placebo. All-cause mortality was reduced by 77.7% over 28 days. (ClinicalTrials.gov number, NCT04728802).Competing Interest StatementKintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren, Dr. McCoy, and Dr. Li are employees of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.Clinical TrialNCT04728802Funding StatementThis investigator-initiated trial was supported by an unconditional research grant from Kintor Pharmaceuticals, Ltd. to Applied Biology, Inc., which provided study drugs at no cost. Kintor Pharmaceuticals, Ltd. had no role in the design of the study, data collection, analysis, interpretation of data, or in writing the manuscript, and provided no financial support to the hospitals, or to investigators.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by an ethics committee and registered in clinicaltrials.gov (NCT04728802), and also approved by Brazilian National Ethics Committee, approval number 4.513.425; CAAE 41909121.0.0000.5553.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset is available under request and specific justification.